The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Drug-coated balloon angioplasty for in-stent restenosis – a question of the right device or the right patient selection and technique?

EuroIntervention 2020;16:e276-e278. DOI: 10.4244/EIJV16I4A47

1. Clinical and Experimental Interventional Cardiology, University of Saarland, Homburg/Saar, Germany


The risk of restenosis after implantation of current-generation drug-eluting stents (DES) is considered to be very low1. However, the number of complex coronary interventions is increasing, often involving a larger number and total length of implanted stents. As a result, about 10% of all coronary interventions represent treatment of in-stent restenosis (ISR) (USA NCDR database). The causes of ISR are complex and multifactorial. The primary mechanism of excessive neointimal proliferation due to the stimulus of the permanent implant is often reinforced by mechanical causes such as insufficient expansion of the stent or fractures of the stent struts. Therefore, ISR therapy ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Stent thrombosis: prevention is the only effective treatment